聶德權指疫苗接種進展不夠快
公務員事務局局長聶德權出席電台節目時表示示,疫苗接種計劃展開一個月,共有43萬名市民接種第一劑疫苗,約5,600人接種第二劑疫苗,認為計劃進展不算緩慢,但亦不夠快。他明白市民對接種疫苗有觀望情緒,但希望市民不要受觀望情緒影響,如果接種疫苗的人數不足,對本港亦會有很大影響。
另外出席同一節目的政府疫苗顧問專家委員會成員曾浩輝就表示,目前仍不建議「溝針」,指本地及外國的確有涉及「溝針」的研究,但只屬初步研究方向,現階段仍然認為接種同一品牌的疫苗較為穩妥。 (el/k) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.